| COVID-19 |
|
| Year : 2020 | Volume
: 7
| Issue : 1 | Page : 31-34 |
|
|
Tuberculosis-prone countries and resistance to COVID-19
Prasanta Kumar Ghosh
Ex-Adviser, Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India
Correspondence Address:
Dr. Prasanta Kumar Ghosh
Ex-Adviser, Department of Biotechnology, Government of India; Block: C2B, Flat: 5A, Janakpuri, New Delhi 110058.
India
 Source of Support: None, Conflict of Interest: None  | 1 |
DOI: 10.4103/mgmj.MGMJ_36_20
|
|
|
The severe acute respiratory syndrome coronavirus 2 (SARS CoV2) also called human coronavirus 2019 (HCoV-19) causing COVID-19 flu originated from China. The complete nucleotide sequence of SARS CoV2 was revealed in January 2020 by Chinese scientists, opening up opportunities for developing therapeutic agents and vaccines. The Chinese people were late in declaring the onset of the disease; only during January 2020, it was revealed that this disease was spreading like an epidemic from man to man contact. The spread of the disease and deaths, in the meantime, were very high in a short period all over the world from man to man contact. To prevent these, use of masks, social distancing among the noninfected and maintaining isolation in houses for a period to allow the surroundings to get absolved from infection, and locking down the infected in hospitals or at home with supportive therapy were effective to prevent the spread. Current country-wise world data on diseased individuals and the deaths reveal that the developing countries having a preponderance of tuberculosis perform better in comparison, to resist the disease with concomitant lesser deaths. The efforts of developing an effective vaccine would require a painstaking, precise understanding of the manner the virus mutates and mount vaccination strategies to effectively neutralize and opsonize. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
